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Blood cell formation is governed by the haemopoietic growth factors that control the 
proliferation, maturation and survival of the haemopoietic progenitor cells via activation 
of receptors expressed on the cell membrane. Most of these receptors share structural 
features and have been grouped in the haemopoietin or class I receptor superfamily. 
Recently considerable progress has been made in elucidating the regions critical for the 
function of these receptors and the signal transduction mechanisms that they activate. 
Moreover, it has become clear that certain clinical haematological onditions can be linked 
to specific defects in these receptors. The significance of defects in the receptor for 
grannlocyte colony-stimulating factor (G-CSF) in the pathogenesis of severe congenital 
neutropenia and acute myeloid leukaemias i  discussed. 
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Haemopoietic growth factors (HGFs) stimulate the proliferation and 
development of haemopoietic precursor cells via binding to specific ell 
surface receptors. The majority of HGF receptors (HGF-R) belong to the 
superfamily of haemopoietin orcytokine receptors, also referred to as the 
class I receptor superfamily (Bazan, 1990; Cosman, 1993). Activation of 
these receptors involves the formation of dimeric or oligomeric omplexes 
of receptor structures. Some HGF-R are composed of heteromeric 
complexes, comprising distinct receptor chains. For example, the receptors 
of interleukin (IL-) 2, IL-3, IL-5 and granulocyte-macrophage colony- 
stimulating factor (GM-CSF) (Miyajima et al, 1993). Other receptors, for 
example those of granutocyte-CSF (G-CSF) and erythropoietin (EPO), are 
thought o form homodimeric omplexes upon growth factor binding 
(Fukunaga et al, 1991; Cosman, 1993). 
Bailli~re ~ Clinical Haematology-- 577 
Vol. 10, No. 3, September 1997 Copyright O 1997, by Baillirre Tindall 
ISBN 0-7020-2367-1 All rights of reproduction in any form reserved 
0950-3536/97/030577 + 11 $12.00/00 
578 I .P .  TOUW 
Severe chronic neutropenia (SCN) and acute myeloid leukaemia (AML) 
are disease conditions characterized by a myeloid maturation arrest in the 
bone marrow. Because SCN patients have a highly increased probability of 
developing AML, it has been postulated that common or functionally over- 
lapping mechanisms may be involved in these diseases. A number of 
research groups have recently paid attention to the possibility that 
abnormalities in responses to GM-CSF and G-CSF, two of the major HGFs 
implicated in the control of myeloid ifferentiation, might contribute to the 
pathogenesis of SCN and AML. 
The major principles of signal transduction from the HGF-Rs will be 
discussed. Next, experimental and clinical evidence for the involvement of
HGF-R abnormalities for the development of disorders of the haemopoietic 
system will be summarized. Finally, the biological and clinical 
consequences of signalling defects of the GCSF receptor in SCN and AML 
will be discussed. 
Structure and signalling function of class I haemopoietin receptors 
Class I receptors are glycoproteins with an extracellular N-terminal 
domain, a single hydrophobic membrane spanning domain and a C- 
terminal cytoplasmic domain. Characteristic of these receptors is the 
cytokine receptor homology region in the extracellular domain that is 
required for HGF binding. The intracellular domains of class I receptors 
show little overall homology. Structure/function a alysis of the G-CSF 
receptor in appropriate c ll line models showed that distinct functional sub- 
domains in the cytoplasmic region of class I type cytokine r ceptors may 
be involved in transduction of proliferation and maturation signals (Dong 
et al, 1993; Fukunaga et al, 1993). More recently, similar findings have 
been reported for differentiation i duced by the thrombopoietin (TPO) 
receptor (Porteu et al, 1996) and the IL-6 signal transducer GP130 
(Yamanaka et al, 1996). 
Although class I cytokine receptors activate cytoplasmic signalling 
substrates via tyrosine (Tyr)-phosphorylation, they do not possess Tyr 
kinase activity themselves. Instead, protein tyrosine phosphorylation f
downstream substrates is achieved via activation of cytoplasmic protein Tyr 
kinases (PTKs). The Janus kinases (JAKs) comprise a PTK family with 
specific structural features that contains at least five members, four of
which (JAKs 1-3, TYK2) were found to play a central role in cytokine 
receptor signalling (Ihle and Kerr, 1995). Mutations in the membrane 
proximal cytoplasmic region that prevent JAK-binding and activation 
completely abolish the proliferative signalling capacities of, for example, 
GM-CSF-R and EPO-R (Miura et al, 1993; Quelle et al, 1994). Thus, 
activation of JAKs is essential for the mitogenic signalling function of 
HGF-Rs. Supporting this, it was found that overexpression f a kinase 
deficient form of JAK2 interfered with EPO-induced proliferative 
responses (Zhuang et al, 1994). Upon activation, JAKs Tyr phosphorylate 
STAT (signal transducer and activator of transcription) proteins. The Tyr- 
phosphorylated STAT proteins form complexes that translocate directly to 
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the nucleus, where they bind to specific transcription regulatory sequences 
in the genomic DNA and induce gene expression. So far, six distinct STAT 
proteins, plus a number of isoforms, have been identified in mammalian 
cells. Because HGF-Rs show specificity in their ability to recruit and 
activate STATs, it was suggested that diversity within the type of STAT 
complexes activated might contribute to the nature of the diverse cellular 
responses to a given HGF (Ihle and Kerr, 1995). Evidence in support of this 
is provided in recent in vivo and in vitro studies in which gene knock-out 
and dominant negative mutant strategies were applied to specifically block 
the expression and/or function of STATs (Mui et al, 1995; Durbin et al, 
1996; Kaplan et al, 1996; Meraz et al, 1996; Shimoda et al, 1996; Takeda 
et al, 1996; Thierfelder et al, 1996). Given the central role of JAKs and 
STATs in driving cellular esponses to various HGFs and cytokines, it may 
be suggested that aberrations in the function of JAKs or STAT function 
would have profound clinical effects. 
The p21R~/MAPkinase pathway is a second major route implicated in 
HGF-R signalling. This route is more complex than the JAK/STAT path- 
way and is activated via a variety of intermediate signalling complexes. 
Adaptor proteins acting upstream of p21Ra~ include Shc, Grb2 and the 
protein tyrosine phosphatase SHP-2. Shc and Grb2, or SHP-2 and Grb2, 
form complexes with the nucleotide exchange factor Sos (Son of 
sevenless), which results in the activation of p21RaL The p21R~ pathway is 
involved in mediating HGF supported survival of haemopoietic cells 
(Kinoshita et al, 1995). Furthermore, signals given via this route have been 
found to cooperate with JAK/STAT signals in controlling cell cycle pro- 
gression. The cooperation between the JAK/STAT and p21R"~ pathways is 
more intimate than was initially thought. Activation of the Ras route by, for 
example, G-CSF-R, cannot be achieved independent of JAKs (Barge et al, 
1996). This is because JAKs are (directly or indirectly) responsible for the 
phosphorylation f Tyr residues in the receptor molecules, which serve as 
binding sites for signalling substrates implicated in the p21 ~S route. The 
opposite is also true that, although phosphorytation  Tyr residues by 
JAKs suffices for STAT complex formation and DNA binding, it appears 
that subsequent induction of transcription by STAT complexes requires an 
additional phosphorylation event, on serine(Ser) esidues (Wen t al, 1995). 
This is achieved via members of the MAPK family, some of which are 
activated via p21R"~ (David et al, 1995). 
Class I cytokine receptor defects in haemopoietic diseases 
Given the strict dependence of haemopoietic progenitor cells on HGFs 
for proliferation, survival and differentiation i vitro, it had been antici- 
pated that mutations n HGF-R genes could have a role in the development 
of certain haemopoietic disorders. Initial evidence in support of this came 
from the demonstration that a truncated form of the TPO-R, previously 
referred to as MPL, that lacks the major part of the extracellular domain, is 
transduced by murine myeloproliferative leukaemia virus (MPLV) and 
immortalizes haemopoietic progenitor cells (Souyri et al, 1990). In 
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addition, it was shown that alterations in the extracellular domain of EPO- 
R and the common ~ chain of IL-3R/IL-5R/GM-CSF-R, which confer 
ligand independent activation of these receptors, contributed o the 
development of erythroid and myeloid leukaemias in mice, respectively 
(Longmore and Lodish, 1991; Jenkins et al, 1995). However, transforming 
mutations in the [3~ receptor chain have so far not been detected in human 
myeloid leukaemia (Freebum et al, 1996). Mutations in growth factor 
receptor genes affecting the signalling function of the receptor proteins 
have been found in four clinical haematological conditions: X-linked 
severe combined immunodeficiency (X-linked SCID), benign erythro- 
cytosis, SCN and AML. The disease locus in X-linked SCID is positioned 
at Xql3.1 and comprises the gene encoding the common chain (Z) of the 
IL-2, IL-7, IL-15 and possibly the IL-4 and IL-13 receptor complexes 
(Noguchi et al, 1993; Puck et al, 1993). X-linked SCID patients express 
mutations in the Yc gene. These mutations are not limited to a single critical 
region, but occur at multiple positions in the gene. They may lead to protein 
truncations or structural alterations in the extracellular domain, giving rise 
to non-ligand binding or soluble forms of the Z protein (Noguchi et al, 
1993; Puck et al, 1993; Voss et al, t994; Pepper et al, 1995). Alternatively, 
a portion of the cytoplasmic domain is truncated, which contains the cyto- 
plasmic SH2 domain of the (y~) receptor sub-unit hat can predictively bind 
to downstream, as yet unidentified, signalling molecules, as well as the 
binding site of the PTK JAK3 (Johnston et al, 1994, Pepper et al, 1995). 
Two sets of observations have established that the inability to activate 
JAK3 specifically determines the disease phenotype in X-linked SCID. 
First, double knock-out ('null') mice lacking JAK3 genes display a SCID 
phenotype that is indistinguishable from that of Z null mice (Disanto et al, 
1995; Nosaka et al, 1995). Second, a number of cases of autosomal SCID 
patients have recently been reported with inactivating mutations in the 
JAK3 gene. These patients display clinical symptoms imilar to X-linked 
SCID (Macchi et al, 1995; Russell et al, 1995). 
Benign erythrocytosis is a dominant autosomal condition characterized 
by a mild increase in red blood cell counts with normal serum levels of 
EPO. The condition ihas been associated with mutations in the EPO-R. So 
far, two pedigrees with distinct types of mutations have been identified. 
One is a nonsense mutation that results in the deletion of 70 carboxy- 
terminal amino acids (De la Chapelle et al, 1993). The second is an 
insertion resulting in a frameshift and a premature stop codon, causing a 
deletion of 64 carboxy-terminal amino acids (Sokol et al, 1995). As a 
result of these truncations, the binding site for the protein tyrosine 
phosphatase SHP-1, at Tyr 449 of EPO,R, is lost (Klingmtiller et al, 1995). 
Because SHP-1 is a negative regulator of JAK2 activation by EPO, the 
mitogenic response to EPO is enhanced as a result of these truncations. 
This provides a plausible mechanistical explanation for the increased red 
blood cell production in these individuals (Youssoufian et al, 1993), which 
is further supported by the observation that SHP-1 deficient (meTme v)mice 
also demonstrate an increased sensitivity to EPO (Van Zant and Schultz, 
1989). 
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G-CSF receptor defects in SCN and AML 
A maturation arrest of granulocytic progenitor cells in the bone marrow 
leads to profound absolute neutropenia n SCN. As a result, patients uffer 
from severe and life threatening opportunistic nfections. SCN diagnosis is 
usually made early in infancy and the disease has a variable inheritance. 
Although SCN was originally described, in Swedish families, as an 
autosomal recessive disorder (Kostmann, 1956), autosomal dominant 
forms of SCN have also been identified. Additionally, SCN cases without a 
family history have been reported. This variability in genetic background 
implicates that SCN is a heterogeneous di ease condition in which defects 
in different genes may give rise to a largely similar disease phenotype. 
Because GM-CSF and G-CSF are major growth factors involved in the 
production of neutrophilic granutocytes, the possibility that SCN patients 
might clinically benefit from treatment with these growth factors has 
received major interest. Initial studies in which SCN patients were treated 
with GM-CSF showed that myelopoiesis was enhanced as a result of the 
treatment, leading to a significant rise in absolute leukocyte counts. 
However, with few exceptions, GM-CSF led to increased eosinophil and 
monocyte counts, whereas neutrophil levels remained low (Vadhan-Raj et 
al, 1990; Welte et al, 1990). These clinical observations indicated that GM- 
CSF treatment of SCN patients is generally not sufficient o restore the 
intrinsic defect in neutrophilic maturation. In contrast, G-CSF treatment of 
SCN patients leads to large increases in functional neutrophils, resulting in 
significant clinical improvement (Bonilla et al, 1989; Welte et al, 1990). 
Therefore, it was hypothesized that reduced levels of biologically active 
G-CSF might be involved in the pathogenesis of SCN. However, pro- 
duction of G-CSF by mononuclear cells and bone marrow stroma cells 
from SCN patients appeared to be normal and G-CSF serum levels often 
higher than normal, which excluded defective G-CSF production as a 
possible cause of neutropenia in these patients (Mempel et al, 1991; Pietsch 
et al, 1991; Guba et al, 1994). 
A randomized, controlled phase III trial showed that 90% of SCN 
patients respond to G-CSF treatment by increases in their absolute 
neutrophil counts, although generally to levels which are still below normal 
(Dale et al, 1993). This resulted in approximately 50% reduction in the 
incidence and duration of infection-related events and almost 70% 
reduction in duration of antibiotic use. In patients in which G-CSF therapy 
does not result in sustained and sufficiently increased numbers of circulat- 
ing neutrophils, infection-related mortality remains a major concern (Ryan 
et al, 1995; Zeidler et al, 1996). 
A second major clinical complication is that SCN patients have an 
increased probability of developing myelodysplasia (MDS) and/or AML 
with poor prognosis (Gillio and Gabrilove, 1993). The incidence of 
progression to leukaemia mong SCN patients registered by the Severe 
Congenital Neutropenia International Registry (SCN-IR) is 16 out of 220 
or 7.27%, as reported in September 1996 (Freedman et al, 1996). The 
follow-up of this cohort of patients, who all received G-CSF therapy, is still 
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relatively short (8 years or less). It is therefore possible that this figure is 
still an underestimation f the frequency of AML progression. 
The variability in clinical responses of SCN patients to G-CSF is a 
further illustration of the heterogeneous nature of SCN. The fact that most 
patients respond to pharmacological but not to normal dosages of G-CSF 
raised the suggestion that abnormalities in the expression or growth factor 
binding abilities of G-CSF-R could play a role in SCN. However, the 
observation that neutrophils from SCN patients expressed normal evels of 
G-CSF-R with normal G-CSF binding affinity argued against his idea 
(Kyas et al, 1992). An alternative xplanation is that the cytoplasmic 
signalling function of G-CSF-R is affected in SCN. Support for this 
possibility came from the identification of an SCN patient with a somatic 
mutation in the G-CSF-R gene (Dong et al, 1994). This mutation resulted 
in the truncation of the C-terminal cytoplasmic region of the G-CSF-R that 
is critical for its maturation signalling function (Dong et al, 1993; Fukunaga 
et al, 1993). The mutation was heterozygous and present in the myeloid 
cells of the patient, but not in other haemopoietic lineages (erythroid, T and 
B lymphocytic) or skin fibroblasts from either the patient or his parents, 
indicating that it had occurred in a progenitor cell committed tothe myeloid 
lineage. Besides lacking maturation signalling abilities, the truncated 
G-CSF-R protein also misses a C-terminal element that negatively 
regulates proliferation (Dong et al, 1994). Experiments in which wildtype 
and mutant G-CSF-R were co-expressed at comparable vels in 32D cells 
showed that maturation signalling fi'om the wildtype form is inhibited by 
the truncated G-CSF-R form in a dominant negative fashion (Dong et al, 
1995a). This, in combination with the fact that the affected myeloid 
progenitor cells had clonally expanded in the patient, suggested that expres- 
sion of the mutant G-CSF-R induced or contributed toa premalignant status 
of the cells. In further support of this, the leukaemic ells from two AML 
patients with a history of SCN also had mutations in G-CSF-R, again 
truncating the C-terminal maturation-inducing re ion (Dong et al, 1995a). 
Among 20 other cases, two additional patients with G-CSF-R mutations in 
the critical region were identified, both of which developed AML. Notably, 
G-CSF-R mutations were not detected in SCN patients from the original 
pedigree of Kostmann, i.e. the autosomal recessive variant (Dong et al, 
1997). 
Tidow et al (1997) recently reported the presence of G-CSF-R nonsense 
mutations in four out of 28 SCN patients. One of these (patient FR) had 
already been i cluded in the analysis of Dong et al (1997), but the others 
represented novel cases. Two of their four patients with G-CSF-R 
mutations, including FR, developed AML. Thus, from a total of 50, seven 
patients (14%) had mutations in the G-CSF-R gene, four of whom showed 
disease progression to AML. Importantly, a G-CSF-R mutation was 
detected after leukaemic progression but not at the neutropenic stage of the 
disease. This patient suffered from an inherited recessive form of SCN, 
with a brother also being severely neutropenic. Neither this affected brother 
nor the healthy parents had a G-CSF-R mutation. These observations 
provided further support for the notion that a G-CSF-R mutation truncating 
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the C-terminal domain is associated with leukaemic progression in SCN, 
but also suggested that this defect had not been the primary cause of the 
neutropenia, t least in this familial form of SCN. 
To establish to what extent G-CSF-R mutations contribute to the disease 
phenotype, experiments in which these mutations are targeted into the 
haemopoietic ells of mice and the consequences studied in vivo are 
warranted. So far, it has been demonstrated that G-CSF or G-CSF-R null 
mice suffer from chronic neutropenia, further establishing the essential role 
of G-CSF in neutrophil development (Lieschke t al, 1994; Liu et al, 1996). 
Strikingly, the neutropenia in these knock-out mice is not as deep as in SCN 
patients. Apparently, other growth factors can to a certain extent substitute 
for G-CSF, as observed by Liu et al. in their G-CSF-R null model (Liu et 
al, 1996). The defects in SCN may be more severe because they affect he 
maturation abilities in such a way that compensatory mechanisms are 
ineffective. In the context of the G-CSF-R mutations, this could be because 
truncated G-CSF-R combine defective maturation with enhanced 
proliferation signalling (Dong et al, 1993). These gross disturbances of the 
proliferation/maturation balance and changes in cell cycle kinetics in 
response to G-CSF could make the compensatory mechanisms ineffective, 
which would explain the accumulation of immature cells in the bone 
marrow that is characteristically observed in SCN patients. 
The majority of SCN patients do not express G-CSF-R mutations. By 
analogy to the severe combined immunodeficiency s ndrome, in which 
mutations in either the Z or Jak3 genes give rise to the same clinical 
symptoms, it is tempting to speculate that these patients could have defects 
in signalling substrates directly downstream of the G-CSF-R. The 
signalling properties of G-CSF-R on bone marrow and blood cells of SCN 
patients have been investigated to a limited extent. For instance, it was 
shown that G-CSF-R, are not hampered in their ability to activate the JAK2 
kinase (Rauprich et al, 1995). Taking into account he localization of the 
G-CSF-R mutations, this is not surprising because activation of JAK2 is 
mediated via the membrane proximal cytoplasmic region of G-CSF-R. 
Rather, potential defects in the signalling function downstream of G-CSF- 
R might be expected to involve substrates activated via the carboxy- 
terminal region of the receptor. 
A STAT family member that is prominently activated by G-CSF is 
STAT3 (De Koning et al, 1996). Although little is known of the target 
genes of activated STAT3 complexes that are implicated in neutrophilic 
maturation, recent work has indicated that STAT3 is involved in IL-6- 
induced macrophage differentiation (Nakajima et al, 1996). G-CSF- 
induced activation of STAT3 depends on the recruitment of STAT3 to the 
G-CSF-R via binding of STAT3-SH2 domains to multiple phospho- 
tyrosines of the activated G-CSF-R. Three of these Tyrs are located in the 
C-terminal region associated with maturation signalling, raising the 
possibility that STAT3 could be involved in the regulation of neutrophilic 
development. However, truncated G-CSF-R forms from SCN patients are 
still able to activate STAT3, indicating that the lack of maturation 
signalling function of the mutant receptors cannot simply be attributed to 
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disturbed STAT3 activation. On the other hand, the truncated G-CSF-R 
forms have lost their ability to activate the Shc protein, involved in the 
p21R~ pathway. Recently it has been demonstrated that Shc activation is 
required for differentiation induction via the TPO-R (Alexander et al, 
1996). In contrast, studies with Tyr substitution mutants of G-CSF-R 
indicated that neutrophilic differentiation induced by G-CSF does not 
depend on Shc activation (De Koning et al, 1997). In fact, it is still unclear 
which signalling substrates are critical for G-CSF-R-induced neutrophilic 
maturation. 
Mutations affecting the function of the G-CSF-R can also be found in 
AML patients without a disease history of congenital neutropenia. Thus far, 
two such cases have been reported. One patient expressed a mutation 
truncating the C-terminal maturation domain, similar to those detected in 
SCN (Carpeti et al, 1997). In the second patient, AML blasts showed high 
expression of a new G-CSF-R splice variant termed SD, in which the 
carboxy-terminus is altered due to a change in the reading frame (Dong et 
al, 1995b). Analysis of cDNA and corresponding enomic sequences 
revealed a G to A transition ext to a (cryptic) splice donor site involved in 
the alternative RNA splicing. The SD splice variant was unable to 
transduce proliferation andmaturation signals upon transfer to murine cell 
systems. In agreement with this, the primary AML blast cells of this patient 
failed to respond to G-CSF in proliferation assays in vitro, whereas the 
responsiveness to IL-3 or GM-CSF was maintained. These observations 
implicate that G-CSF-R dysfunction, either caused by structural defects in 
the G-CSF-R (rarely) or by abnormalities in downstream signalling com- 
ponents mediating maturation signalling, can play a role in the patho- 
genesis of de novo AML. 
Acknowledgements 
This work was supported by the Dutch Cancer Society and the Netherlands Organization for Scientific 
Research (NWO). 
REFERENCES 
Alexander WS, Maurer AB, Nova& U & Harrison-Smith M (1996) Tyrosine-599 of the c-Mpl receptor 
is required for She phosphorylation and theinduction of cellular differentiation. EMBO Journal 
15:6531-6540. 
Barge RMY, de Koning JP & Pouwels K etal (1996) Tryptophan 650 of human granulocyte colony- 
stimulating factor (G-CSF) receptor, implicated in the activation of JAK2, is also required for 
G-CSF-mediated activation of signaling complexes of the p21Ras route. Blood 87: 2148- 
2153. 
Bazan JF (1990) Structural design and molecular evolution of a cytokine receptor superfamily. 
Proceedings of the National Academy of Sciences of the USA 87: 6934-6938. 
*Bonilla MA, Gillio AP, Ruggeiro Met al (1989) Effects of recombinant human granulocyte colony- 
stimulating factor on neutropenia in patients with congenital agranulocytosis. New England 
Journal of Medicine 320: 1574-1580. 
Carapeti M, Soede-Bobok AA, Hochhaus A et al (1997) A dominant negative mutation of the G-CSF 
receptor truncating he C-terminal maturation domain in a patient with acute myeloid leukemia 
without congenital neutropenia. L ukemia 11: 1005-1008. 
G-CSF, NEUTROPENIA AND MYELOID LEUKAEMIA 585 
De la Chapelle A, Tr~iskelin AL & Juvonen E (1993) Truncated erythropoietin receptor causes 
dominantly inherited benign human erythrocytosis. Proceedings of the National Academy of 
Sciences of the USA 90: 4495-4499. 
Cosman D (1993) The hematopoietin receptor superfamily. Cytokine 5: 95-106. 
*Dale DC, Bonilla MA, Davis MW et al (1993) A randomized controlled phase III trial of recombinant 
human granulocyte colony-stimulating factor (Filgrastim) for treatment of severe chronic neu- 
tropenia. Blood 81: 2496-2502. 
David M, Petricoin III E, Benjamin C et al (1995) Requirement for MAP kinase (ERK2) activity in 
interferon co- and interferon 13-stimulated gene expression through STAT proteins. Science 269: 
1721-1723. 
Disanto JP, Muller W, Guy-Grand D et al (1995) Lymphoid evelopment i  mice with a targeted ele- 
tion of the interleukin-2 receptor yc chain. Proceedings of the National Academy of Sciences of 
the USA 92: 377-381. 
*Dong F, Van Buitenen C, Pouwels K et al (1993) Distinct cytoplasmic regions of the granulocyte 
colony-stimulating factor receptor involved in induction of proliferation and maturation. 
Molecular and Cellular Biology 13:7774-7781. 
*Dong F, Hoefsloot LH, Schelen AM et al (1994) Identification of a nonsense mutation in the 
granulocyte colony-stimulating factor eceptor in severe congenital neutropenia. Proceedings of 
the National Academy of Sciences of the USA 91: 4480-4484. 
*Dong F, Brynes RK, Tidow Net al (1995a) Mutations truncating the C-terminal maturation region of 
the G-CSF receptor in acute myeloid leukemia preceded by severe congenital neutropenia. New 
England Journal of Medicine 333: 487-493. 
Dong F, Van Paassen M, Van Buitenen C et al (1995b) A point mutation in the granulocyte colony- 
stimulating factor receptor (G-CSF-R) gene in a case of acute myeloid leukemia results in the 
overexpression f a novel G-CSF-R isoform. Blood 85:902-912. 
Dong F, Dale DC, Bonilla MA et al (1997) Mutations in the granulocyte colony-stimulating factor 
gene in patients with severe congenital neutropenia. Leukemia 11: 120-t25. 
Durbin JE, Hackenmiller R, Simon MC & Levy DE (1996) Targeted isruption of the mouse Stat 1 
gene results in compromised innate immunity to viral disease. Cell 85: 443-450. 
Freeburn RW, Gale RE, Wagner HM & Linch DC (1996) The beta subunit common to the GM-CSF, 
IL-3 and IL-5 receptors i highly polymorphic but pathogenic point mutations in patients with 
acute myeloid leukaemia (AML) are rare. Leukemia 10: 123-129. 
Freedman MH, Bonitla MA, Boxer Let  al (1996) MDS/AML in patients with severe chronic 
neutropenia (SCN) receiving G-CSE Blood 88 (supplement 1): $448. 
*Fukunaga R, Ishizaki-Ikeda E & Nagata S (1993) Growth and differentiation signals mediated by dif- 
ferent regions in the cytoplasmic domain of granulocyte colony-stimulating factor eceptor. Cell 
74: 1079-1087. 
Fukunaga R, Ishizaka-Ikeda E, Pan C-X et al (1991) Functional domains of the granulocyte colony- 
stimulating factor eceptor. EMBO Journal 10: 2855-2865. 
Gillio AP & Gabrilove JL (1993) Cytokine treatment of inherited bone marrow failure syndromes. 
Blood 81: 1669-1674. 
Guba SC, Sartor CA, Hutchinson R et al (1994) Granulocyte colony-stimulating factor (G-CSF) pro- 
duction and G-CSF receptor structure in patients with congenital neutropenia. Blood 83: 
t486-1492. 
lhle JN & Kerr IM (1995) Jaks and Stats in signaling by the cytokine receptor superfamily. Trends in 
Genetics 11: 69-74. 
Jenkins B J, D'Andrea R & Gonda TJ (1995) Activating point mutations in the common 13 subunit of 
the human GM-CSE IL-3 and IL-5 receptors suggest the involvement of ~ subunit dimerization 
and cell type-specific molecules in signalling. EMBO Journal 14: 4276--4287. 
Johnston JA, Kawamura M, Kirken RA et al (1994) Phosphorylation and activation of the Jak-3 
kinase in response to interleukiu-2. Nature 370: 151-153. 
Kaplan MH, Sun Y-L, Hoey T & Grusby MJ (1996) Impaired IL-12 responses and enhanced 
development ofTh cells in Stat-4-deficient mice. Nature 382: 174--177, 
Kinoshita T, Yokota T, Arai K-I & Miyajima A (1995) Suppression of apoptotic death in hemato- 
poietic cells by signalling through the IL-3/GM-CSF receptors. EMBO Journal 14: 266- 
275. 
*Klingmtiller U, Lorenz U, Cantley LC et al (1995) Specific recruitment of SH PTP 1 to the erythro- 
poietin receptor causes inactivation of JAK2 and termination f proliferative signals. Cell 80: 
729-738. 
586 i .P .  Touw 
De Koning JP, Dong F, Smith Let al (1996) The membrane-distal cytoplasmic region of human 
granulocyte colony-stimulating factor receptor is required for STAT3 but not STATI homodimer 
formation. Blood 87: 1335-1342. 
De Koning JR Smith L, Schelen AM et al (1997) Distinct mechanisms of p21Ras activation by G- 
CSF receptor: implications f r G-CSF mediated regulation of proliferation and neutrophilic mat- 
uration. Blood 88 (supplement 1): $446, 
Kostmann R (1956) Infantile genetic agranulocytosis. Acta Paediatrica Scandinavia, 45 (supplement 
105): S1-$78. 
Kyas U, Pietsch T & Welte K (1992) Expression of receptors for granulocyte colony-stimulating fac- 
tor on neutrophils from patients with severe congenital neutropenia and cyclic neutropenia. 
Blood 79: 1144-1147. 
*Lieschke GJ, Grail D, Hodgson Get ai (t994) Mice lacking granulocyte colony-stimulating factor 
have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired 
neutrophil mobilization. Blood 84: 1737-1746. 
*Liu E Wu HY, Wesselschmidt R et al (1996) Impaired production and increased apoptosis of 
neutrophils in granulocyte colony-stimulating factor recept deficient mice. Immunity 5: 
491-501. 
Longmore GD & Lodish HF (1991) An activating mutation in the murine erythropoietin receptor 
induces erythroleukemia in mice: a cytokine receptor superfamily oncogene. Cell 1991: 
1089-1102. 
Macchi P, Villa A & Gillani S (1995) Mutations of Jak-3 gene in patients with autosomal severe 
combined immunodeficiency (SCID). Nature 377: 65~68. 
Mempel K, Pietsch T, Menzel T et al (1991) Increased serum levels of granulocyte colony-stimulating 
factor in patients with severe congenital neutropenia. Blood 77: 1919-1922. 
Meraz MA, White JM, Sheehan KCF et al (i996)Targeted disruption of the Statl gene in mice reveals 
unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442. 
Miura O, Cleveland JL & lhle JN (1993) Inactivation f erythropoietin receptor function by point 
mutations in a region having homology with other cytokine receptors. Molecular and Cellular 
Biology 13: 1788-1795. 
Miyajima A, Mui ALE Ogorochi T & Sakamaki K (1993) Receptors for granulocyte-macrophage 
colony-stimulating factor, interleukin-3, and interleukin-5. Blood 82: 1960-1974. 
Mui ALF, Wakao H, O'Farrell AM et al (1995) Interleukin-3, grunulocyte-macrophage colony- 
stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO 
Journal 14: 1166-1175. 
Nakajima K, Yamanaka Y, Nakae K et al (1996) A central role f r Stat3 in IL-6-induced regulation of 
growth and differentiation in M1 leukemia cells. EMBO Journal 15: 3651-3658. 
*Noguchi M, Yi H, Rosenblatt HM etal (1993) Interleukin-2 receptor 2t chain mutation results in X- 
linked severe combined immunodeficiency in humans. Cell 73: 147-157. 
Nosaka T, Van Deursen JM & Tripp RA (1995) Defective lymphoid development in mice lacking 
JAK3. Science 270: 800--802. 
Pepper AE, Buckley RH, Small TN & Puck JM (1995) Two mutational hotspots in he interleukin-2 
receptor gamma chain gene causing human X-linked severe combined immunodeficiency. 
American Journal ofHuman Genetics 57: 564-571. 
Pietsch T, Biihrer C, Mempel K etal (1991) Blood mononuclear cells from patients with severe con- 
genital neutropenia are capable of producing granulocyte colony-stimulating factor. Blood 77: 
1234-1237. 
Porteu E Rouyez MC, Cocault Le  al (1996) Functional regions of the mouse thrombopoietin 
receptor cytoplasmic domain: evidence for a ritical region which is involved in differentiation 
and can be complemented by erythropoietin. Molecular and Cellular Biology 16: 2473-2482. 
Puck JM, Deschenes SM, Porter JC et al (1993) The interleukin-2 receptor gamma chain maps to 
Xql3.1 and is mutated in severe combined immunodeficiency, SC1DX1. Human Molecular 
Genetics 2: 1099-1104. 
Quelle FW, Sato N & Witthuhn BA (1994) Jak2 associates with the [3o chain of the receptor for 
granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane- 
proximal region. Molecular and Cellular Biology 14: 4335-4341. 
Rauprich P, Kasper B, Tidow N & Welte K (1995) The protein tyrosine kinase JAK2 is activated in 
neutrophils from patients with severe congenital neutropenia. Blood 86: 4500-4505. 
Russell SM, Tayebi N, Nakajima Hetal (1995) Mutation f JAK3 in a patient with SCID: essential 
role of JAK3 in lymphoid development. Science 270: 797-800. 
G-CSF, NEUTROPENIA AND MYELOID LEUKAEMIA 587 
Ryan M, Will AM, Testa Net al (1995) Severe congenital neutropenia unresponsive to G-CSE British 
Journal of Haematology 91: 43--45. 
Shimoda K, van Deursen J, Sangster MY et al (1996) Lack of IL-4-induced Th2 response and IgE 
class switching in mice with disrupted Stat6 gene. Natur  380: 630-633. 
Sokol L, Luhovy M, Guan Y et al (t995) Primary familial potycythemia: a frameshift mutation in the 
erythropoietin receptor gene and increased sensitivity of rythroid progenitors  erythropoietin. 
Blood 86: 15-22~ 
Souyri M, Vigon I, Penciolelli J-F et al (1990) A putative truncated cytokine receptor g n  transduced 
by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63: 
1137-1147. 
Takeda K, Tanaka T, Shi Wet al (1996) Essential role of Stat6 in IL-4 signalling. Nature 380: 
627-630. 
Thierfetder WE, van Deursen JM, Yamamoto K et al (1996) Requirement for Star4 in interleukin-12 
mediated responses of natural killer cells. Nature 382: 171-I74. 
Tidow N, Pilz C, Teichmann Bet al (1997) Clinical relevance of point mutations i  the granulocyte 
colony-stimulating factor receptor g ne in patients with severe congenital neutropenia. Blood 89: 
2369-2375. 
Vadhan-Raj S, Jeha SS, Buescher S et al (1990) Stimulation of myelopoiesis n a patient with 
congenital neutropenia: biology and nature of response to recombinant human granulocyte- 
macrophage colony-stimulating factor. Blood 75: 858-864. 
Voss SD, Hong R & Sondel PM (1994) Severe combined immunodeficiency, intefleukin-2 (IL-2), and 
the IL-2 receptor: experiments of ature continue to point the way. Blood 83: 626-635. 
Welte K, Zeidler C, Reiter A et al (1990) Differential effects of granulocyte-macrophage colony- 
stimulating factor and granulocyte colony-stimulating factor in children with severe co genital 
neutropenia. Blood 75: 1056-1063. 
Wen Z, Zhong Z & Darnell JE (1995) Maximal activation of transcription by Stat 1 and Stat3 requires 
both tyrosine and serine phosphorylation. Cell 82: 241-250. 
Yamanaka Y, Nakajima K, Fukada T et al (1996) Differentiation and growth arrest signals are 
generated through the cytoplasirfic region of gpl30that is essential forStar3 activation. EMBO 
Journal 15: 1557-1565. 
Youssoufian H, Longmore G, Neumann D et al (1993) Structure, function and activation of the Epo 
receptor. Blood 81: 2223-2236. 
Van Zant G & Schultz L (1989) Hematologic abnormalities of the immunodeficient mouse mutant, 
viable motheaten (mev). Experimental Hematology 17: 81-87. 
Zeidler C, Bonilla MA, Boxer L t  al (t996) Report on patients with severe chronic neutropenia 
(SCN) refractory toG-CSE Blood 88 (supplement 1): $349, 
Zhuang H, Patel SV, He T et al (1994) Inhibition f erythropoietin-induced mitogenesis by a kinase- 
deficient form ofJak2. Journal of Biological Chemistry 269:214t 1-21414. 
